| Atomoxetine for freezing of gait in Parkinson disease. | |
| | |
MedLine Citation:
|
PMID: 19361809 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Freezing of gait (FoG) is one of the most troublesome symptoms associated with Parkinson disease (PD). This symptom usually does not respond to dopaminergic therapy, possibly because it is mediated via noradrenergic, rather than dopaminergic, deficiency. As atomoxetine enhances noradrenergic transmission we postulated that it may be effective in the treatment of FoG and enrolled 5 PD patients who had this gait abnormality, both when "on" or "off" levodopa, into a double-blind, randomized trial. Although an improvement in total Gait and Balance Scale (GABS) score was noted in patients treated with atomoxetine as compared to placebo, this did not reach statistical significance, possibly because of a small sample size. Further studies in a larger population of patients with FoG are needed to determine whether atomoxetine is a useful drug in the treatment of this, often disabling, feature of PD. |
| | |
Authors:
|
Joseph Jankovic |
Related Documents
:
|
9617719 - Additional therapies in parkinson's disease patients: useful tools for the improvement ... 17691309 - Motor cortex stimulation for parkinson's disease. 11409119 - Combined use of power doppler and gray-scale sonography: a new technique for the assess... 17612949 - Primary and secondary features of parkinson's disease improve with strategic exposure t... 8596149 - Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythem... 3286439 - Randomized, double-blind trial of exifone versus cognitive problems in parkinson's dise... 22286639 - The loss of smell in persistent allergic rhinitis is improved by levocetirizine due to ... 20091549 - Withdrawn. endoscopic retrograde cholangiopancreatography in gallstone-associated acute... 15892489 - Presentiment or entanglement? an alternative explanation for apparent entanglement in p... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2009-04-09 |
Journal Detail:
|
Title: Journal of the neurological sciences Volume: 284 ISSN: 1878-5883 ISO Abbreviation: J. Neurol. Sci. Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-05 Completed Date: 2009-12-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375403 Medline TA: J Neurol Sci Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 177-8 Citation Subset: IM |
Affiliation:
|
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, United States. josephj@bcm.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic Uptake Inhibitors
/
therapeutic use* Aged Antiparkinson Agents / therapeutic use Double-Blind Method Female Gait Disorders, Neurologic / drug therapy*, etiology Humans Levodopa / therapeutic use Male Middle Aged Parkinson Disease / complications*, drug therapy Propylamines / therapeutic use* Severity of Illness Index |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic Uptake Inhibitors; 0/Antiparkinson Agents; 0/Levodopa; 0/Propylamines; 83015-26-3/atomoxetine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gene Transfer of COX-1 Improves Lumen Size and Blood Flow in Carotid Bypass Grafts.
Next Document: Epstein-Barr virus and multiple sclerosis.